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transporter. However, prolonged pre-incubation with the 
studied inhibitors greatly enhanced the effect on mitox-
antrone accumulation. The inhibitors caused a significant 
time-dependent reduction in the expression of ABCG2 
in the resistant cells, an effect that would improve drug 
efficacy.
Conclusion Consequently, it appears that the Pim1 inhibi-
tors display a dual-mode effect on ABCG2-expressing 
cancer cells. This may provide a powerful new strategy in 
overcoming drug resistance by targeting proteins that regu-
late expression of efflux pumps.
Keywords Multidrug resistance · BCRP · ABCG2 · Pim1 
kinase · Cancer chemotherapy
Introduction
Chemotherapy remains a vital treatment strategy in cancer, 
and unfortunately, the multidrug-resistant phenotype con-
tinues to confound its efficacy. Multidrug resistance com-
prises numerous cellular processes that are either inherent 
to the tissue or acquired during chemotherapy. The plasma 
membrane is at the front line of resistance and utilises a 
triad of drug efflux pumps from the ATP-binding cassette 
(ABC) family. The three pumps have distinct pharmacolog-
ical profiles and distinct expression patterns in cancer. The 
focus of this investigation is on ABCG2, which is known 
to confer resistance to flavopiridol, mitoxantrone, metho-
trexate and topotecan [1, 2]. The protein is expressed in 
cultured cell lines of fibrosarcoma, myeloma, ovarian and 
breast cancer. Human cancers known to express the protein 
include digestive tract, lung and endometrial adenocarci-
nomas, soft-tissue sarcomas and haematological malig-
nancies [2–6]. At the clinical level, there are no effective 
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Purpose Multidrug efflux pumps such as ABCG2 confer 
drug resistance to a number of cancer types, leading to poor 
prognosis and outcome. To date, the strategy of directly 
inhibiting multidrug efflux pumps in order to overcome 
drug resistance in cancer has been unsuccessful. An alter-
native strategy is to target proteins involved in the regula-
tion of multidrug efflux pump activity or expression. Pim1 
kinase has been demonstrated to phosphorylate ABCG2, 
promote its oligomerisation and contribute to its ability to 
confer drug resistance.
Methods In the present manuscript, imidazo-pyridazine-
based inhibitors of Pim1 were examined for their ability to 
overcome ABCG2-mediated drug resistance. Drug efficacy 
was measured as a cytotoxic response or an effect on trans-
port by ABCG2. Protein expression patterns were assessed 
using western immuno-blotting.
Results The two Pim1 inhibitors increased the potency 
of flavopiridol, mitoxantrone, topotecan and doxorubicin, 
specifically in ABCG2-expressing cells. This effect was 
associated with an increase in the cellular accumulation 
of [3H]-mitoxantrone, suggesting direct impairment of the 
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strategies to overcome the resistant phenotype produced by 
ABCG2, although a number of compounds inhibit its activ-
ity in vitro. Developing strategies to overcome the action of 
ABCG2 are important, particularly given its wide expres-
sion profile in cancers and the number of cytotoxic drugs 
affected by its influence.
A homodimeric assembly of ABCG2 is required to gen-
erate a fully functional drug transport protein. The precise 
oligomeric status remains contentious with evidence from 
co-immunoprecipitation [7] and low-resolution cryo-EM 
studies indicating the presence of higher-order oligom-
ers [8]. The protein is a member of the G-subfamily and 
comprises an amino-terminal nucleotide-binding domain 
(NBD) and a transmembrane domain (TMD) containing 
six helices [1]. This “reverse” topological arrangement is 
distinct from other subgroups of the ABC family. The pro-
tein is glycosylated on the asparagine at position 596 [9], 
which is located in the extracellular loop between TM heli-
ces 5 and 6. This loop also contains an intramolecular disul-
phide bond between cysteine residues at positions 592 and 
608 and an intermolecular disulphide bond between pairs 
of cysteine 603 [10]. The precise roles of glycosylation and 
disulphide bond formation in ABCG2 function remain unre-
solved, but they are crucial to the folding and stability of the 
protein. The region at the interface between homodimeric 
units remains to be elucidated, although a GXXXG motif 
between positions 406 and 410 has been implicated [11].
ABCG2 has numerous consensus sites for phosphoryla-
tion, although there is little information on the state of its 
phosphorylation in cells [1, 12, 13]. However, phosphoryla-
tion of ABCG2 has been suggested to be a prerequisite for 
its expression at the plasma membrane with a report show-
ing that activation of protein kinase B (AKT) results in an 
increase in the amount of ABCG2 at the plasma membrane, 
whilst inactivation of AKT results in internal retention of 
ABCG2 [12]. Moreover, the interaction has a functional 
consequence since it has been shown in haematopoietic 
stem cells that the efflux of the ABCG2 substrate Hoechst 
33342 was positively correlated with the activity of AKT 
[14].
Activated AKT has also been shown to bind to the pro-
lactin response element found on the Pim1 promoter [15]. 
Pim1 kinase is a serine/threonine kinase encoded by a 
proto-oncogene known to be expressed in several cancers 
[16]. Two isoforms of the kinase are known to be pro-
duced by alternative translation start sites yielding a 33 and 
44 kDa protein. The 44 kDa kinase may exist as a dimer, 
whilst the 33 kDa isoform is monomeric [17]. Whilst the 
33 kDa kinase regulates the cell cycle and transcription by 
phosphorylating numerous participants in these processes, 
including cdc25A, HP1 and p100 [18–21], the 44 kDa 
kinase has been shown to interact with ABCG2 [13]. It has 
been postulated that Pim1 phosphorylates the threonine at 
position 362 in ABCG2, which was proposed to modulate 
the dimerisation and/or multimerisation of ABCG2 [13]. 
The Thr362 residue in ABCG2 is found in a Pim1 com-
patible recognition sequence: (Lys)3–Ile–Thr–Val [22]. In 
a taxane-resistant prostate cancer cell line overexpressing 
P-gp, treatment with SGI-1776 (a novel inhibitor of Pim1)
re-sensitised the cell line to paclitaxel, suggesting a poten-
tial role for Pim1 kinase in multidrug resistance [23].
Compounds based on an imidazo-[1,2-b]-pyridazine 
scaffold have been found to inhibit Pim1 kinase at nanomo-
lar affinity in vitro [24–26] by forming hydrogen bond 
and hydrophobic interactions with the binding pocket, 
thereby perturbing ATP binding. This class of compounds 
displays selectivity for the Pim1 kinase domain over the 
Pim2 isoform. K00135 and K00486 (Fig. 1) were identi-
fied as the best compounds of this series to bind to Pim1 
with a high affinity and inhibit its activity [27]. The present 
study investigated the effects of the Pim1 kinase inhibitors 
K00135 and K00486 on ABCG2-mediated drug resist-
ance in the MCF7FLV1000 cell line. The data suggest that the 
inhibitors are able to overcome drug resistance by a dual 
mechanism involving direct inhibition of ABCG2 and by 
altering its expression.
Fig. 1  Pim inhibitor structures. 
The chemical structures of the 
Pim1 kinase inhibitors K00135 
(left panel) and K00486 (right 
panel). The inhibitors were 
based on the imidazo-[1,2-b]-
pyridazine template molecule
Materials and methods
Reagents
The imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors 
were synthesised in the Knapp Laboratory and stored at a con-
centration of 50 mM in DMSO. The ABCG2-specific inhibitor 
fumitremorgin C (FTC), doxorubicin, topotecan and mitox-
antrone were purchased from Sigma-Aldrich and prepared as 
50 mM aliquots in DMSO. Mitoxantrone (Tocris) was pre-
pared at 50 mM in DMSO, and flavopiridol (Biomol Inter-
national) was prepared at 10 mM in DMSO. All compounds 
were stored at −20 °C. [3H]-mitoxantrone (148 GBq/mmol)
was purchased from Moravek Biochemicals (Brea, USA). 
The anti-ABCG2 (BXP-21) and the anti-Pim antibody (12H8) 
were purchased from Santa Cruz Biotechnology and the goat 
anti-mouse horseradish peroxidase-conjugated antibody from 
DAKO. The ECL Prime chemi-luminescence detection kit 
was purchased from GE. All plasticware was purchased from 
either Fisher Scientific UK or Greiner Bio-One.
Cell lines
A549 (lung), DLD-1 (colorectal), H226 (lung), HT-29 (colo-
rectal), LnCaP (prostate), PC3 (prostate), MCF7 (breast) and 
the ABCG2-overexpressing MCF7FLV1000 cell lines were cul-
tured in RPMI 1640 medium (Invitrogen Life Technologies) 
supplemented with 10 % foetal calf serum and 1 % penicil-
lin/streptomycin (Lonza). Flavopiridol (500 nM) was added 
to the medium of the MCF7FLV1000 cell line every fourth sub-
culture to maintain selection pressure for ABCG2 expression. 
Cells were maintained for a further passage before use. The 
Jurkat and K562 leukaemic cell lines were grown under simi-
lar conditions but as suspension cultures. The P-gp-expressing 
and drug-resistant NCI/ADRRes cell line was cultured in the 
presence of 3 mM doxorubicin for a single passage every ten 
passages to maintain the selection pressure The resistant NCI/
ADRRes cell line was cultured in the presence of 3 μM doxo-
rubicin for a single passage every ten passages to maintain the 
selection pressure [35]. This cell line was formerly known as 
the MCF7Adr line and has been redesignated as described in 
Ref. [23, 28].
Cytotoxicity assays
Cells were seeded in flat-bottomed 96-well plates at a den-
sity of 2500 cells per well and allowed to attach to the sur-
face for 24 h at 37 °C, 5 % CO2. The effects of single drug 
treatment on the viability of the cell lines were evaluated 
after incubation for 5 days with various concentrations of 
Pim kinase inhibitors (10−8–10−4 M) or chemotherapeutic 
agents (10−12–10−4 M).
For combination drug treatment, MCF7 and MCF-
7FLV1000 cell lines were incubated with chemotherapeutic 
agents (10−12–10−4 M) in the absence or presence of FTC 
(0.3 µM), K00135 (0.1 or 0.3 µM), K00486 (0.3 or 1.0 µM) 
or an equivalent volume of DMSO as a vehicle/solvent con-
trol and allowed to incubate for 5 days at 37 °C, 5 % CO2. 
Cells were subsequently fixed in 10 % trichloroacetic acid 
for 30 min at 4 °C. The plates were then washed with five 
rounds of water and stained with 0.075 % (w/v) sulforhoda-
mine B (SRB) for 15 min at room temperature. Excess SRB 
was removed from the plates with four washes of 1 % (v/v) 
acetic acid and the SRB-stained viable cells solubilised 
with 10 mM Trizma pH10.5. Absorbance was detected on a 
SpectraMax Plus 384 (Molecular Devices) at 540 nm using 
SoftMax®Pro data acquisition and analysis software. For the 
nonadherent leukaemia cells, the MTS assay was used to 
measure cell density and viability as described [29].
Data from either assay were subsequently analysed and 
graphically depicted using GraphPad Prism software, using 
one-way ANOVA. Drug toxicity was quantified by nonlin-
ear regression of the general dose–response equation:
where F is the viable cell number, Fmax and Fmin are the 
maximum and minimum cell number, respectively, IC50 is 
the concentration causing 50 % cell death, and [D] is the 
logarithm of drug concentration. At least four independ-
ent experiments were performed, and relative resistance 
values were established by dividing the IC50 value of the 
MCF7FLV1000 cell line for each drug by the IC50 value of the
MCF7 cell line.
Cellular accumulation of [3H]‑mitoxantrone
ABCG2-mediated transport was assessed by the steady-
state accumulation of [3H]-mitoxantrone. Fifty thousand 
cells well−1 were seeded in sterile 24-well plates and incu-
bated at 37 °C, 5 % CO2 overnight. Pim1 kinase inhibitors 
or FTC was added to the wells and allowed to incubate for 
various times as specifically indicated in the results. The 
medium was subsequently discarded from the plate and 
replaced with 0.5 ml of drug transport buffer (107 mM 
NaCl, 10 mM Tris. HCl pH7.4, 26 mM NaHCO3, 5.3 mM 
KCl, 1.9 mM CaCl2, 1 mM MgCl2, 7 mM glucose) con-
taining a total mitoxantrone concentration of 1 μM, which 
contained 40 nM of the tracer [3H]-mitoxantrone. FTC or 
Pim kinase inhibitor were also added to the transport buffer 
with radioligand where required. The plate was incubated 
as above for a period of 3 h before discarding the buffer 
and washing the wells three times with 0.5 ml of ice-cold 
PBS. The cells were lysed with 0.5 ml 0.1 M NaOH and the 
F = Fmin +
Fmax − Fmin
1+ 10(log10(IC50)−[D])
amount of mitoxantrone determined by liquid scintillation 
with 3.5 ml of ReadyProtein scintillation fluid for 5 min. 
The radioactive decay was converted to nmoles of mitox-
antrone accumulated per milligram of cell protein using the 
specific activity of the radioligand.
Western immuno‑blot analysis
Cells were washed with PBS and lysed with 1 % (w/v) SDS 
and subsequently sheared with a fine gauge needle. Protein 
concentration was determined using the detergent compat-
ible DC Bio-Rad assay using BSA as a standard. Samples 
of lysate (5–20 μg as indicated in figure legends) were sub-
jected to SDS-PAGE using 10 % (w/v) gels and then trans-
ferred to nitrocellulose. The nitrocellulose was blocked 
for 1 h with 5 % (w/v) nonfat dried milk in PBS contain-
ing 0.1 % (v/v) Tween 20. The antibodies were diluted 
according to the manufacturer’s protocols in 5 % (w/v) 
nonfat dried milk in PBS containing 0.1 % (v/v) Tween 20 
and incubated with the nitrocellulose overnight. Follow-
ing washing in PBS containing 0.1 % (v/v) Tween 20, the 
nitrocellulose was incubated with goat anti-mouse HRP 
secondary antibody for 1 h. The immuno-blots were devel-
oped using ECL Prime chemi-luminescence according to 
the manufacturer’s instructions, exposed to Hyperfilm ECL 
and analysed by densitometry using ImageJ software.
Results
Imidazo-[1,2-b]-pyridazine inhibitors have previously been 
demonstrated to interact with the nucleotide-binding site 
of Pim1. The two inhibitors (K00135 and K00486) used in 
this investigation (Fig. 1) were generated from structure–
activity relationships with Pim1, and they represent two of 
the most potent available Pim1 inhibitors.
Growth inhibitory effects of Pim1 kinase inhibitors 
in cultured cancer cell lines
Initial studies with Pim1 kinase inhibitors explored their 
ability to prevent cell growth in a range of tumour cell 
lines including leukaemia and lymphoma cells, and cell 
lines derived from solid tumours. Both Pim1 inhibitors 
produced growth arrest in all the investigated cell lines in 
the micromolar range (Table 1), with potencies that did not 
differ significantly between K00135 and K00486; however, 
there were differences in potency when comparing between 
cell lines. Table 1 also shows the relative potencies of 
Pim1 inhibitors in comparison with conventional cytotoxic 
anti-cancer drugs in a number of cell lines derived from 
solid tumours. All cell lines used in this table express the 
Pim1 protein, and none have ABCG2 expression at levels 
detectable by western blotting (data not shown). The data 
were obtained following a 96-h exposure of cells to cyto-
toxic drugs or Pim1 inhibitors. Shorter incubation (24 h) 
with the Pim1 inhibitors did not alter the efficacy (i.e. 
the maximal effect on growth arrest), although the poten-
cies of each compound were marginally reduced (data not 
shown). The Pim1 inhibitors are regarded as anti-prolifer-
ative agents, and therefore, the longer incubation period 
was chosen for comparison with the effects of cytotoxic 
anti-cancer drugs. As expected, the various anti-cancer 
drugs displayed considerable variation in the IC50 values 
for cytotoxicity, with a rank order of potency of: vinblas-
tine > doxorubicin > mitoxantrone > etoposide > cisplatin. 
Table 1  Effects of Pim1 inhibitors on the growth of cultured human cancer cells
Cells were seeded at 2 × 103  cells per well (total volume = 100 μl) in a 96-well tissue culture plate and incubated for 24 h prior to addition
of drugs. Anti-cancer drugs and the two Pim kinase inhibitors were prepared in medium at double the desired concentration and 100 μl added 
to each well. Vinblastine was added in the final concentration range 10−12–10−5 M and all other drugs in the range 10−10–10−4 M. Cells were 
incubated for 96 h with the drugs. Cell number and viability were measured with the SRB assay for adherent cultures and with MTS for suspen-
sion cultures (i.e. K562 and Jurkat). Cell density was plotted as a function of cytotoxic drug concentration and the IC50 values (units shown in 
parentheses) determined using nonlinear regression of the general dose–response equation. The values shown represent mean ± SEM from four
to six independent experiments
Drug K562 Jurkat PC3 LNCaP HT-29 H226 DLD-1 A549
K00135 (µM) 12 ± 6 2.0 ± 1.1 4.7 ± 2.0 3.9 ± 0.4 19 ± 16 13 ± 5 11 ± 5 28 ± 4
K00486 (µM) 3.9 ± 1.4 1.3 ± 0.5 4.4 ± 1.5 2.0 ± 0.5 11 ± 5 3.8 ± 2.3 4.4 ± 1.7 13 ± 8
Cisplatin (µM) 5.2 ± 1.8 1.8 ± 0.9 3.8 ± 1.7 12 ± 8 4.7 ± 1.2 14 ± 5 11 ± 6 19 ± 6
Etoposide (nM) 44 ± 8 89 ± 39 287 ± 47 175 ± 25 530 ± 170 102 ± 40 250 ± 119 467 ± 133
Methotrexate (nM) 2.7 ± 0.6 19 ± 9 0.67 ± 0.67 54 ± 19 10 ± 4 41 ± 17 25 ± 9 37 ± 11
Doxorubicin (nM) 3.2 ± 0.8 2.5 ± 0.5 22 ± 4 7.6 ± 2.5 26 ± 10 66 ± 59 9.6 ± 2.3 47 ± 31
Vinblastine (nM) 0.04 ± 0.01 0.04 ± 0.01 0.15 ± 0.07 0.11 ± 0.06 0.31 ± 0.10 0.29 ± 0.14 1.81 ± 0.91 0.76 ± 0.35
Mitoxantrone (nM) 2.6 ± 0.8 0.11 ± 0.07 4.8 ± 1.4 1.6 ± 0.6 6.4 ± 3.4 0.84 ± 0.32 3.2 ± 0.7 2.2 ± 0.3
The anti-cancer drugs displayed potencies in the nanomolar 
range, with the exception of cisplatin, which was effective 
at micromolar concentrations.
The primary focus of the investigation was to exam-
ine the relative efficacy of Pim1 inhibitors between drug-
sensitive and multidrug-resistant cells expressing the ABC 
transporter ABCG2. The breast cancer cell line MCF7WT 
was exposed to increasing concentrations of flavopiridol to 
select for drug-resistant cells as described [2]. The result-
ant drug-resistant cell line is referred to as MCF7FLV1000, 
and as shown in Fig. 2, it is associated with expression of 
ABCG2. Furthermore, the cell line displays expression of 
the 45kD and the 33kD isoforms of Pim kinase. The paren-
tal MCF7WT cell line does not express ABCG2 at levels 
detected by western immuno-blotting; however, it does 
express both Pim1 isoforms (data not shown). Figure 3a 
demonstrates that K00135 produces growth inhibitory 
effects on the MCF7WT (IC50 = 2.7 ± 0.5 μM) and MCF-
7FLV1000 cell lines (IC50 = 1.1 ± 0.3 μM). The small dif-
ferences in relative Pim1 inhibitor sensitivity of the two 
cell lines were not statistically significant, although the 
data were described by different relationships. Curve fitting 
of the variable slope and unity slope dose–response rela-
tionships was compared using an F test. A variable slope 
equation provided the most suitable (F test; P < 0.001) fit 
to the experimental data with MCF7WT cells characterised 
by a slope of −2.6, whereas the MCF7FLV1000 cells were
best described by the equation with a slope of 1.0. Data for 
the effects of K00486 on the growth of both cell lines are 
shown in Fig. 3b. K00486 inhibited growth of MCF7WT 
cells with an IC50 of 1.9 ± 0.2 μM and with an IC50 of
2.6 ± 0.1 μM in the MCF7FLV1000 cells. The experimental
data in the parental cells were again best described with a 
variable slope (F test; P < 0.0001) with a value of −4.4.
The difference is likely due to the complexity of eliciting 
cytotoxicity in cell lines that had been selected for drug 
resistance. The slope factor did not influence the value of 
potency (IC50) to produce a cytotoxic effect. 
The similarity in potency for the Pim1 kinase inhibitors 
on drug-sensitive and drug-resistant (ABCG2-overexpress-
ing) cells suggests that the compounds are not substrates 
for transport by ABCG2.
Fig. 2  Expression of ABCG2 and Pim1 in breast cancer cells. Cell 
lysates were prepared from the drug-resistant MCF7FLV1000 cell line 
in 1 % SDS and total protein determined colorimetrically. SDS-PAGE 
(10 % gels) and western blot analysis was performed on lysate sam-
ples containing 5, 10, 15 and 20 μg protein. The amounts loaded 
(μg) on each well are denoted by the values above the lanes. The left 
panel shows a blot probed with the anti-ABCG2 antibody BXP-21. 
The arrow indicates the location of the 72kD ABCG2 protein. The 
blot shown in the right panel was probed with the anti-Pim antibody 
12H8. The arrows correspond to the 33 and 45kD isoforms of Pim1 
kinase. Both proteins were detected using an anti-mouse secondary 
antibody with subsequent chemi-luminescence
Fig. 3  Anti-proliferative effects of the imidazo-[1,2-b]-pyridazine-
based Pim1 kinase inhibitors on breast cancer cells. The growth 
inhibitory effects of a K00135 and b K00486 were measured in 
MCF7 (open symbols, dashed lines) and MCF7FLV1000 (closed sym-
bols, solid lines) cell lines. Cells (2.5 × 103 well−1) were seeded in
96-well plates and grown with various concentrations (10−8–10−4 M)
of the inhibitors for 5 days. The cell density following incubation 
with inhibitors was measured using the sulforhodamine B assay. The 
data were fitted with the variable slope dose–response curve using 
nonlinear regression and shown are the mean ± SD of three inde-
pendent experiments
Chemosensitisation of MCF7FLV1000 cells by Pim1 
kinase inhibitors
The ability of Pim1 inhibitors to produce growth inhibi-
tion even in drug-resistant cell lines suggests that they may 
facilitate the activity of conventional anti-cancer drugs. 
Therefore, the potency and efficacy of a series of geno-
toxic anti-cancer drugs in the absence or presence of Pim1 
inhibitors were assessed in MCF7 and MCF7FLV1000 cells. 
Dose–response analysis was used to generate an IC50 for 
the anti-cancer drug and the degree of resistance calculated 
(Table 2). The concentrations of Pim1 inhibitors used were 
threefold to tenfold lower than the IC50 values obtained for 
their ability to effect cell growth when added alone.
The cyclin-dependent kinase inhibitor flavopiridol 
inhibited growth of the parental MCF7 cell line with an 
IC50 of 52.6 ± 7.3 nM, and the potency was reduced to
2017 ± 78 nM in the ABCG2-expressing MCF7FLV1000
cells. The ratio of IC50 values indicates that the level of 
resistance to this drug was 38-fold. In the presence of the 
ABCG2 inhibitor FTC (0.3 μM), there was no significant 
effect on potency in MCF7 cells; however, the IC50 value 
was reduced to 193 ± 30 nM in the resistant line. The
reduced potency revealed a significant reduction in the 
level of resistance to 4.5-fold by inhibiting the activity of 
ABCG2. Addition of Pim1 inhibitors also caused signifi-
cant increase in the potency of flavopiridol and in each case 
reduces the level of drug resistance. Neither compound 
altered the efficacy or potency of Flavopiridol to generate 
growth inhibition in the drug-sensitive MCF7 cells.
Mitoxantrone, a topoisomerase II inhibitor, also dis-
played reduced potency in drug-resistant MCF7FLV1000 
cells (IC50 = 525 ± 69 nM) compared to the parental
MCF7 cells (IC50 = 12.9 ± 3.1 nM). This 40-fold resist-
ance to mitoxantrone was reduced to 15-fold by 0.3 μM 
FTC. In the MCF7FLV1000 cells, the Pim1 inhibitor K00135 
reduced the level of mitoxantrone resistance to 24-fold at 
a concentration of 0.1 μM (IC50 = 209 ± 51 nM) and a
further reduction to 13-fold at a concentration of 0.3 μM 
(IC50 = 81 ± 21 nM). Similar reductions in mitoxantrone
resistance were obtained for K00486, and once again, there 
were no effects of Pim1 inhibitors on the cytotoxicity of 
mitoxantrone towards MCF7 cells.
The greatest level of drug resistance observed in the 
MCF7FLV1000 cells (336-fold) was conferred against the 
topoisomerase I inhibitor topotecan. The potency of 
topotecan was improved from IC50 = 2736 ± 127 nM to
IC50 = 163 ± 27 nM in the presence of 0.3 μM FTC,
which represents a reduction in the level of resistance 
to 35-fold. The Pim1 inhibitor K00486 (1.0 μM) also 
reduced the level of topotecan resistance to 35-fold 
and improved the potency of the cytotoxic drug to 
177 ± 13 nM. K00135 also improved the potency of
topotecan, although the level of improvement was not 
as large as observed for K00486 at the concentrations 
tested.
Table 2  Effects of Pim1 inhibitors on anti-cancer drug efficacy in MCF7 and MCF7FLV1000 cells
Cells were seeded at 2 × 103  cells per well in a 96-well tissue culture plate and incubated for 24 h prior to drug addition. Cytotoxic drugs were
then added to the cells in the presence or absence of Pim1 inhibitors and the ABCG2 inhibitor fumitremorgin C. The plates were incubated for 
a further 5 days and the cell density measured using the sulforhodamine B assay. Cell density was plotted as a function of cytotoxic drug con-
centration and the IC50 values (μM) determined using nonlinear regression of the general dose–response equation. The values shown represent 
mean ± SEM from four independent experiments. The degree of resistance refers to the ratio of cytotoxic potency in the MCF7FLV1000 compared
to the MCF7 cells. The symbol (*) represents a statistically significant (P < 0.01) difference from the control group (i.e. no Pim1 or ABCG2 
inhibitor). Statistical comparisons were made using ANOVA, with the Bartlett’s post hoc test
Cytotoxic drug Cell line Chemosensitisation agent
Control FTC
0.3 μM
K00135
0.1 μM
K00135
0.3 μM
K00486
0.3 μM
K00486
1.0 μM
Flavopiridol MCF7 52.6 ± 7.3 42.7 ± 5.9 57.7 ± 4.6 52.7 ± 5.9 44.7 ± 6.6 40.4 ± 5.3
MCF7FLV1000 2017 ± 78 193 ± 30* 728 ± 87* 201 ± 20* 347 ± 24* 153 ± 11*
Resistance 38.3 4.5 12.6 3.8 7.8 3.8
Mitoxantrone MCF7 12.9 ± 3.1 5.9 ± 1.9 8.7 ± 1.8 6.2 ± 0.9 6.3 ± 2.9 6.4 ± 1.7
MCF7FLV1000 525 ± 69 86 ± 4* 209 ± 51* 81 ± 21* 174 ± 49* 35 ± 12*
Resistance 40.7 15.5 24.1 13.1 27.4 5.4
Topotecan MCF7 8.1 ± 1.3 4.5 ± 0.4 6.3 ± 0.7 5.2 ± 0.5 6.8 ± 1.1 4.9 ± 0.8
MCF7FLV1000 2736 ± 127 163 ± 27* 1315 ± 86* 353 ± 32* 571 ± 15* 177 ± 13*
Resistance 336 35.9 210 68.1 83.6 35.8
Doxorubicin MCF7 8.5 ± 0.8 9.0 ± 1.2 11.1 ± 0.52 6.6 ± 0.6 12.8 ± 2.1 9.7 ± 1.1
MCF7FLV1000 69.9 ± 6.9 29.8 ± 3.7 62.6 ± 3.3* 34.7 ± 4.8* 34 ± 4.2* 24.5 ± 3.6*
Resistance 8.2 3.3 5.6 5.2 2.7 2.5
The well-characterised R482G mutant isoform of 
ABCG2 imparts a number of changes in the cross-resist-
ance pattern compared to the wild-type isoform. The latter 
has a considerably lower degree of resistance to the widely 
used anthracycline doxorubicin. Table 2 demonstrates that 
the degree of resistance in MCF7FLV1000 cells compared to 
their parental control was only eightfold, which was lower 
than the other compounds tested. Nonetheless, the degree 
of resistance was reduced to threefold by the ABCG2 inhib-
itor FTC at a concentration of 0.3 μM. Both K00135 and 
K00486 were able to potentiate the cytotoxicity of doxoru-
bicin in the MCF7FLV1000 cells, but not the parental control.
The data in Table 2 demonstrate that expression of 
ABCG2 confers resistance to a number of anti-cancer drugs 
and that pharmacological inhibition of this transporter (by 
FTC) can overcome the phenotype. More importantly, 
inhibitors of Pim1 also produce a dose-dependent reduction 
in the degree of resistance by augmenting the potency of 
each of the anti-cancer drugs tested. The mechanism under-
lying how Pim1 inhibitors improve the potency of anti-can-
cer drugs requires further investigation.
The ability of K00135 and K00486 to overcome mul-
tidrug resistance in cells expressing ABCB1 was assessed 
using a similar strategy. As shown in Table 3, the NCI-
ADR/Res cell line that expresses ABCB1 displayed con-
siderable resistance (526-fold) to doxorubicin compared 
to the parental MCF7 cells. The ABCB1 inhibitor vera-
pamil (3 μM) increased the potency of doxorubicin from 
IC50 = 2736 ± 127 nM to IC50 = 86 ± 14 nM (P < 0.05),
exclusively in the drug-resistant cells. This represents a 
reduction in the degree of resistance from 526- to 32-fold. 
However, the addition of Pim1 inhibitors did not cause any 
alteration in the potency of doxorubicin or the degree of 
resistance. This indicates that the two compounds K00135 
and K00486 produced inhibition specific to ABCG2 and 
not ABCB1.
The effects of Pim1 inhibitors on the steady‑state 
accumulation of [3H]‑mitoxantrone in MCF7FLV1000 
cells
The Pim1 inhibitors were shown in the previous section 
to overcome drug resistance to a number of anti-cancer 
drugs in cell lines selected for resistance to flavopiridol. 
The drug resistance of MCF7FLV1000 is primarily due to 
overexpression of the ABC transporter ABCG2. Conse-
quently, the mechanism underlying the circumvention 
of drug resistance by the inhibitors is likely to involve 
altered accumulation of anti-cancer drugs. To investigate 
this mechanistic issue, the steady-state accumulation of 
the ABCG2 substrate [3H]-mitoxantrone was investigated 
in the two cell lines. Initially, the accumulation was meas-
ured in the presence, or absence, of the specific ABCG2 
inhibitor FTC as shown in Fig. 4a. An incubation period 
of 3 h was required to achieve steady-state accumulation 
of the radiolabelled drug at a total concentration of 1 μM. 
The accumulation of [3H]-mitoxantrone in MCF7 cells 
was 2.44 ± 0.22 pmol mg−1 in the absence of FTC, and
the value was 1.47 ± 0.15 pmol mg−1 in MCF7FLV1000
cells, which represents a statistically significant difference 
(P < 0.005). The addition of increasing concentrations of 
FTC (0.5–10 μM) did not alter the accumulation of [3H]-
mitoxantrone in the MCF7 cells since the level at the high-
est FTC concentration (2.62 ± 0.21 pmol mg−1) was not
significantly different from the control value. In contrast, 
the ABCG2 inhibitor produced a dose-dependent increase 
in the accumulation of [3H]-mitoxantrone in MCF7FLV1000 
cells to a level (2.61 ± 0.36 pmol mg−1 at 10 μM FTC)
that was identical to the sensitive MCF7 cells.
Parallel analysis was undertaken to assess the ability of 
Pim1 kinase inhibitors to modulate the steady-state accu-
mulation of [3H]-mitoxantrone. These experiments were 
carried out either with the Pim1 kinase inhibitor present 
Table 3  Effects of verapamil and Pim1 inhibitors on anti-cancer drug efficacy in MCF7 and ABCB1-expressing NCIADR/Res cell lines
Cells were seeded at 2 × 103  cells per well in a 96-well tissue culture plate and incubated for 24 h prior to drug addition. Cytotoxic drugs were
then added to the cells in the presence or absence of Pim1 inhibitors and the ABCB1 inhibitor verapamil. The plates were incubated for a further 
5 days and the cell density measured using the SRB assay. Cell density was plotted as a function of cytotoxic drug concentration and the IC50 
values (nM) determined using nonlinear regression of the general dose–response equation. The values shown represent mean ± SEM from four
independent observations. The degree of resistance refers to the ratio of cytotoxic potency in the MCF7FLV1000 compared to the MCF7 cells. The 
symbol (*) represents a statistically significant (P < 0.01) difference from the control group (i.e. no Pim1 or ABCB1 inhibitor). Statistical com-
parisons were made using ANOVA, with the Bartlett’s post hoc test
Cytotoxic drug Cell line Chemosensitisation agent
Control Verapamil
3 μM
K00486
0.3 μM
K00486
1 μM
K00135
0.1 μM
K00135
0.3 μM
Doxorubicin MCF7 4.2 ± 1.4 2.7 ± 0.5 3.3 ± 1.0 4.1 ± 1.0 4.5 ± 1.2 3.4 ± 0.7
NCIADR/Res 2211 ± 387 86 ± 14* 2076 ± 557 2232 ± 627 2950 ± 780 3094 ± 786
Resistance 526 32 629 544 655 910
only during the transport incubation (acute treatment), or 
when the cells had been pre-incubated with the Pim1 inhib-
itor (for 21, 45 and 69 h; chronic treatment) (Fig. 4b, c). 
The data were normalised to the level of [3H]-mitoxantrone 
accumulation observed in the absence of Pim1 inhibitor, 
which was set to a value of 1.0. The increased exposure to 
Pim inhibitors reveals any long-term cellular effects on the 
activity or expression of Pim kinase.
Figure 4b demonstrates that the addition of K00135 did 
not result in any alteration of [3H]-mitoxantrone accumula-
tion in the MCF7 cell line, regardless of the incubation time. 
In contrast, the acute addition of K00135 (2 μM) produced 
a 2.6-fold increase in the steady-state accumulation of [3H]-
mitoxantrone in MCF7FLV1000 cells (comparable to the two-
fold change in accumulation effected by FTC treatment; 
Fig. 4a). This result in MCF7FLV1000 cells suggests a direct 
effect on the activity of ABCG2. Additionally, we observed 
that extended pre-incubation of these cells with K00135 
produced a significant, and time-dependent, increase in the 
accumulation of [3H]-mitoxantrone. These data suggest that 
the compound also produces a chronic effect on ABCG2 
activity resulting from inhibition of Pim1 kinase.
Similarly, Fig. 4c shows the effects of K00486 (2 μM) 
on [3H]-mitoxantrone accumulation in the two cell lines. 
Similarly, the Pim1 inhibitor did not generate any signifi-
cant alterations in radiolabel accumulation in the drug-
sensitive MCF7 cells. However, there were time-dependent 
alterations of [3H]-mitoxantrone in the drug-resistant MCF-
7FLV1000 cells. The accumulation was increased 1.9-fold 
where there was no pre-incubation with K00486, and fol-
lowing a 69-h pre-incubation, the level had been increased 
over fivefold. [3H]-Mitoxantrone accumulation was also 
increased using a higher concentration of Pim1 inhibitors 
(i.e. 4 μM); however, this did not differ markedly from the 
observations reported for the lower concentration. In addi-
tion, the prolonged exposure of MCF7FLV1000 cells to the 
direct-acting ABCG2 inhibitor FTC (5 μM) did not result 
in a similar time-dependent modification of mitoxantrone 
accumulation (data not shown).
In summary, the Pim1 inhibitors appear to display both 
short- and long-term effects on the accumulation of the 
ABCG2 substrate [3H]-mitoxantrone in the MCF7FLV1000 
cell line. There were no effects in the drug-sensitive MCF7 
cells, suggesting that this effect was specifically related to 
ABCG2. Short-term effects are likely to involve direct inhi-
bition of the protein although the 3-h duration of this assay 
does not entirely rule out post-translational effects. The 
long-term effects are likely to involve altered expression 
and/or post-translational modification of ABCG2.
Fig. 4  [3H]-mitoxantrone accumulation in breast cancer cell lines. 
a MCF7 (open bars) and MCF7FLV1000 (filled bars) grown in 6-well 
plates were incubated with [3H]-mitoxantrone for 3 h. Cells were also 
grown in the presence of varying concentrations (0.5–10 μM) of the 
ABCG2 inhibitor FTC. Following incubation, the cells were washed 
and lysed and the amount of [3H]-mitoxantrone determined by scin-
tillation counting. MCF7 (open symbols, dashed lines) and MCF-
7FLV1000 (filled symbols, solid lines) grown in 6-well plates were incu-
bated with [3H]-mitoxantrone in the presence or absence of 4 μM, 
b K00135 or c K00486. Cells were pre-incubated with Pim kinase 
inhibitors for periods shown in the graphs prior to addition of [3H]-
mitoxantrone. Following incubation with radiolabel, the cells were 
washed and lysed and the amount of [3H]-mitoxantrone determined 
by liquid scintillation counting. Accumulation of [3H]-mitoxantrone 
was expressed as a fraction of that obtained in the absence of Pim 
kinase inhibitor in each cell lines. The data shown represent the 
mean ± SD of three independent experiments
The effects of Pim1 inhibitors on total expression 
of ABCG2 in MCF7FLV1000 cells
The ability of the Pim1 inhibitors to alter the expression of 
ABCG2 was investigated by western blot analysis on MCF-
7FLV1000 cells following incubation with the compounds for 
8 days. Data on the expression levels of ABCG2 are shown 
in Fig. 5.
Figure 5a demonstrates a representative western 
immuno-blot of ABCG2 expression for MCF7FLV1000 cells 
in the absence or presence of 4 μM K00486 over an 8-day 
period. The intensity of ABCG2 bands was quantified 
using densitometry and the results from four preparations 
expressed as a function of culture time (Fig. 5b). The ini-
tial time point was obtained 24 h following cell seeding and 
displayed low-level ABCG2 expression. During the 8-day 
culture period, the expression of ABCG2 increased fivefold 
to sixfold in the MCF7FLV1000 cells. In contrast, in the pres-
ence of Pim1 inhibitors, the expression of ABCG2 did not 
alter significantly during this period and remained similar 
at day 8 compared to day 0.
The expression data reveal a considerable reduction in 
the levels of ABCG2 in MCF7FLV1000 cells following the 
addition of Pim inhibitors. Thus, the ability of these com-
pounds to overcome drug resistance is also related to the 
progressive diminution of ABCG2 expression. This effect 
is in addition to the ability to interact directly with ABCG2 
and thereby impair cytotoxic drug efflux.
Discussion
The investigation has revealed that multidrug resistance 
conferred by ABCG2 was overcome by two imidazo-pyri-
dazine derivatives, which had previously been developed as 
specific inhibitors of the serine/threonine kinase Pim1. Ear-
lier studies have demonstrated that co-expression of Pim1 
and ABCG2 produces increased resistance and that the 
proteins share a physical interaction [13]. In this study, we 
have shown that both inhibitors overcame ABCG2-medi-
ated resistance by directly modulating transport of the sub-
strate mitoxantrone. Further investigation on the transport 
process additionally revealed a longer-term effect that was 
associated with reduced expression of ABCG2 in the can-
cer cell lines. This two-pronged approach provides a novel 
alternative to the classical approach of exclusively targeting 
the transporter. Potent and selective modulation of regula-
tory kinase proteins may alleviate the problems with devel-
oping specific inhibitors of polyspecific drug transporters 
such as ABCG2, as we provided evidence that K00135 and 
K00486 are themselves not transport substrates of ABCG2.
Amongst the earliest reports on the function of Pim 
kinase were the observations that the protein weakly 
transformed mesenchymal cells to generate lymphoma 
and leukaemia [30, 31]. Furthermore, elevated expression 
of Pim kinase was observed in human myeloid leukae-
mia and lymphoma [32, 33]. As the biology of the kinase 
became more widely investigated, a role in solid tumours 
became apparent, with expression demonstrated in pros-
tate, gastric, hepatic, bladder and colorectal tumours [16, 
23, 34, 35]. The tumour growth stimulating properties of 
Pim kinase [36, 37] render the protein a target for thera-
peutic intervention in cancer. The present investigation 
demonstrated growth inhibition of a panel of cancer cell 
lines derived from haematological malignancies and solid 
tumours by two potent imidazo-pyridazine-based inhibitors 
of Pim kinase. This efficacy further supports an inherent 
role for Pim kinases in tumour biology. The potency of the 
Pim inhibitors to produce growth inhibition was in the low 
micromolar range, which was similar to cisplatin, but lower 
than most cytotoxic chemotherapy drugs.
In the last decade, medicinal chemistry efforts have gen-
erated several classes of Pim kinase inhibitors [38, 39]. The 
“boom” in production of inhibitor compounds has benefited 
Fig. 5  Effects of Pim1 kinase inhibitors on the expression of ABCG2 
in cancer cells. MCF7FLV1000 cells were grown in the absence or pres-
ence of Pim kinase inhibitors for up to 8 days. a Cell lysates were 
prepared from the drug-resistant MCF7FLV1000 cell line in 1 % SDS 
and total protein determined colorimetrically. SDS-PAGE (10 % gels) 
and western blot analysis was performed on lysate samples contain-
ing 4 μg protein. ABCG2 was detected using the BXP-21 antibody. 
The upper panel shows ABCG2 expression in the absence of inhibi-
tor and the lower panel in the presence of 4 μM K00486. The panels 
represent data from a representative experiment. b Relative ABCG2 
expression was quantified using densitometry and plotted as a func-
tion of time in culture. The MCF7FLV1000 cells were grown in the 
presence of DMSO control (black bars), 4 μM K00135 (white bars) 
or 4 μM K004865 (hashed bars). The data represent mean ± SEM
from four independent experiments
from the availability of high-resolution structural data for 
Pim kinases [24]. For example, the K00135 inhibitor used 
in the present study co-crystallises with Pim1, and numer-
ous derivatives have been developed from knowledge of the 
molecular interactions underpinning binding [24].
The ABCG2-expressing cells displayed considerable 
differences in the level of resistance to a range of anti-can-
cer drugs and other compounds, as shown in Table 1 and 
in the review by Nakanishi et al. [40]. The range of resist-
ance (and the relative order) to anti-cancer drugs in the cur-
rent investigation is in broad agreement with previous work 
using the MCF7FLV1000 cell line [2]. The mycotoxin FTC 
was one of the first inhibitors of ABCG2 to be identified 
by virtue of its ability to restore sensitivity of drug-resist-
ant cell lines to topotecan, mitoxantrone and doxorubicin 
[41]. The potency of FTC to overcome ABCG2-mediated 
resistance was in the range 0.1–5 μM. In the present inves-
tigation, a fixed concentration of FTC (0.3 μM) produced 
a reduction in the extent of resistance by a factor of up to 
tenfold and thereby restored sensitivity to anti-cancer drugs 
to levels similar to the MCF7 cell line.
The potencies of K00135 and K00486 to inhibit Pim1 
kinase have been demonstrated as 0.12 and 0.04 μM, 
respectively, whereas the potency to inhibit Pim2 kinase 
was reduced by up to 50-fold [24]. Both Pim1 kinase inhib-
itors, at concentrations of 0.1–1 μM, were able to reduce 
the extent of resistance to anti-cancer drugs in the MCF-
7FLV1000 cell line. Furthermore, the potencies and efficacies 
were similar to that of FTC. In addition, the potencies to 
overcome the resistant phenotype in ABCG2-expressing 
cells were similar to another imidazo-pyridazine compound 
SGI-1776, which reached late-stage clinical trials [42]. 
In contrast to the inhibitor SGI-1776, which was able to 
inhibit and overcome the actions of ABCB1 in cancer cell 
lines [42], K00135 and K00486 were selective for ABCB1. 
However, SGI-1776 differs markedly in chemical structure 
from K00135/K00486, despite the common imidazo-pyri-
dazine moiety. It is therefore likely that the different sub-
stituents in SGI-1776 enhance its ability to interact directly 
with ABCB1.
These data clearly indicate that inhibition of Pim kinase 
can overcome the resistant phenotype produced by expres-
sion of ABCG2 and the subsequent focus was to ascertain 
the underlying mechanism. It has been widely demonstrated 
that ABCG2 confers resistance in the MCF7FLV1000 cell line 
by preventing accumulation of drugs such as mitoxantrone 
[2, 41]. The assay required a long incubation period (i.e. 
3 h) in order that the accumulation of [3H]-mitoxantrone 
reached a steady state, which is in agreement with previous 
studies [2, 41]. The addition of both Pim kinase inhibitors 
increased the extent of mitoxantrone accumulation, which 
suggests a direct interaction between the Pim inhibitors and 
ABCG2. SGI-1776 was shown to produce similar effects 
on mitoxantrone accumulation in ABCG2-expressing cells 
[42]. Classically, inhibitors of multidrug efflux pumps 
from the ABC family have been generated to interact with 
the drug-binding site and thereby reduce the rate of sub-
strate translocation. However, the Pim inhibitors used in 
this study were designed to bind at the catalytic domain of 
the kinase. The Pim1 protein has an ATP-binding domain 
that is distinct from most kinases [24, 38]. Structural data 
demonstrated that K00135 and K00486 do not bind to the 
“kinase hinge region” as predicted, but to the novel N-ter-
minal helix within the catalytic region. Therefore, although 
they interact at the ATP-binding domain, they are not con-
sidered ATP mimetics. Consequently, this provides a high 
selectivity for the catalytic domain of Pim proteins and 
only interacted with one other protein from a panel of over 
fifty Ser/Thr kinases [24]. Therefore, it is highly unlikely 
that K00135 and K00486 interact with the ATP-binding 
domain of ABC transporters such as ABCG2.
Thus, the short-term effects of the Pim1-kinase inhibi-
tors are likely to be mediated either through direct effects 
on ABCG2 activity per se, or via indirect effects on 
ABCG2 phosphorylation by Pim1. An investigation by Xie 
et al. [13] provides considerable evidence for the latter. For 
example, the two proteins are co-expressed in several drug-
resistant cell lines and co-localise at the plasma membrane. 
The investigation also suggested that threonine-362 in 
ABCG2 was phosphorylated by Pim1. Knocking down the 
expression of Pim1 reduced the oligomerisation of ABCG2, 
which rendered the cells sensitive to mitoxantrone and dox-
orubicin. This suggests that Pim1 is an important factor in 
the multidrug-resistant phenotype conferred by ABCG2. 
This confirms our observation that pharmacological inhibi-
tion of Pim1 kinase is able to overcome ABCG2-mediated 
resistance. Moreover, it supports the proposal that Pim1 
kinase inhibitor-mediated disruption of [3H]-mitoxantrone 
accumulation may be due to disruption of the stability of 
ABCG2 oligomers at the plasma membrane.
In parallel with post-translational effects on ABCG2 
activity, we also have provided evidence for a chronic effect 
on ABCG2 expression level. Culture of MCF7FLV1000 cells 
revealed a hyperbolic increase in ABCG2 expression, which 
was severely reduced in the presence of both Pim1 kinase 
inhibitors. A precedent for this has already been observed; 
surface expression of ABCG2 was reduced in cells treated 
with another Pim kinase inhibitor, SGI-1776 [42]. Control 
of ABCG2 expression is complex, involves numerous over-
lapping pathways and is frequently cell, or tissue, specific 
[40, 43]. Two of the most frequently observed control fac-
tors for ABCG2 expression are Pim kinase and the PI3K/
AKT signalling pathway [13, 14, 27]. For example, inhibi-
tion of BCR–ABL by imatinib in resistant K562 leukaemic 
cells was associated with post-transcriptional regulation of 
ABCG2 expression via PI3K/AKT [44]. It is tempting to 
speculate that the K00135/K00486-mediated reduction in 
ABCG2 expression involves the coordinated effects of Pim 
kinase and the PI3K/AKT pathway at a transcriptional or 
post-transcriptional level. The pathway or mechanism of 
interaction and synergy between these two factors remains 
to be established to date.
The data indicate that Pim kinase inhibition by the 
two imidazo-pyridazine compounds is able to circumvent 
ABCG2-mediated multidrug resistance. The mechanism 
underlying this effect is by reducing the expression level of 
ABCG2 in the cells. Based on previous findings that Pim 
kinase and ABCG2 share a physical interaction [13], it is 
tempting to speculate that phosphorylation of ABCG2 is 
important in the stability of the protein at the plasma mem-
brane. Moreover, it provides further proof that the drug-
resistant phenotype may be circumvented or overcome via 
modulation of regulatory protein activity and in the case of 
ABCG2, Pim kinase is a key target.
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